CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +7.1% ·
share flow +9.1% ·
net new positions +6.7%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 2 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.08M | +9.0% | $752.51M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 2.18M | — | $402.66M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 1.23M | +1.2% | $227.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 1.23M | +1.2% | $227.04M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 535.68K | +1.8% | $98.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 372.22K | +1952.2% | $68.71M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 13 | PRIMECAP Management ✦ | 272.98K | -0.2% | $50.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 232.32K | +25.8% | $42.89M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 171.22K | -1.0% | $31.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 171.22K | -1.0% | $31.61M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 170.63K | +1101.8% | $31.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 170.63K | +1101.8% | $31.50M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 123.69K | +59.9% | $22.83M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 84.66K | New | $15.63M | 0.0% | New | 1 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 78.86K | +309.6% | $14.56M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | Baillie Gifford ✦ | 75.41K | +9.9% | $13.92M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 25 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 26 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 27 | Marshall Wace ✦ | 21.61K | -93.0% | $3.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 20.98K | -53.0% | $3.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $15.63M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 555 holders, 56.84M shares, $9.32B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.04K sh · $599,711
Director · 573 sh · $163,443
Officer · 3.71K sh · $1.04M
Officer, Director · 6.50K sh · $1.82M
Director · 28.73K sh · $7.90M
Officer · 404 sh · $104,446
Officer · 1.21K sh · $311,529
Officer · 736 sh · $190,278
Officer · 4.18K sh · $1.08M
Officer · 1.27K sh · $330,055
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology